182 related articles for article (PubMed ID: 19268585)
1. Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
Heidebrecht RW; Chenard M; Close J; Dahlberg WK; Fleming J; Grimm JB; Hamill JE; Harsch A; Haines BB; Hughes B; Kral AM; Middleton RE; Mushti C; Ozerova N; Szewczak AA; Wang H; Wilson K; Witter DJ; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2009 Apr; 19(7):2053-8. PubMed ID: 19268585
[TBL] [Abstract][Full Text] [Related]
2. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Witter DJ; Harrington P; Wilson KJ; Chenard M; Fleming JC; Haines B; Kral AM; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Jan; 18(2):726-31. PubMed ID: 18060775
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
4. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
5. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
[TBL] [Abstract][Full Text] [Related]
7. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
8. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
[TBL] [Abstract][Full Text] [Related]
10. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
[TBL] [Abstract][Full Text] [Related]
12. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and comparative reactivity of human class I and class IIb histone deacetylases.
Schultz BE; Misialek S; Wu J; Tang J; Conn MT; Tahilramani R; Wong L
Biochemistry; 2004 Aug; 43(34):11083-91. PubMed ID: 15323567
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
15. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase.
Marson CM; Mahadevan T; Dines J; Sengmany S; Morrell JM; Alao JP; Joel SP; Vigushin DM; Charles Coombes R
Bioorg Med Chem Lett; 2007 Jan; 17(1):136-41. PubMed ID: 17046252
[TBL] [Abstract][Full Text] [Related]
17. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
18. HDAC2 deficiency and histone acetylation.
Ree AH; Folkvord S; Flatmark K
Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
[No Abstract] [Full Text] [Related]
19. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
[TBL] [Abstract][Full Text] [Related]
20. Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.
Nishino N; Shivashimpi GM; Soni PB; Bhuiyan MP; Kato T; Maeda S; Nishino TG; Yoshida M
Bioorg Med Chem; 2008 Jan; 16(1):437-45. PubMed ID: 17900911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
